Molecular Partners Ltd

MOLN

Equity

ISIN CH0256379097 / Valor 25637909

SIX Swiss Exchange (2025-12-19)

CHF 3.58+6.55%

Molecular Partners Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Molecular Partners Ltd is a clinical-stage biopharmaceutical company based in Switzerland, specializing in the development of a novel class of therapeutic proteins known as DARPins (Designed Ankyrin Repeat Proteins). These proteins are engineered to address complex medical conditions, offering potential advantages over traditional antibodies due to their small size, high specificity, and ability to engage multiple targets simultaneously. The company focuses on creating innovative treatments for diseases with significant unmet medical needs, including oncology and infectious diseases. Molecular Partners collaborates with various pharmaceutical companies to advance its pipeline and leverage its proprietary technology platform. Under the leadership of CEO Patrick Amstutz, who co-founded the company in 2004, Molecular Partners has established numerous commercial partnerships and continues to expand its research and development efforts to bring new therapies to market.

Summarized from source with an LLMView SourceSector: Technology

Strong Financial Position

Molecular Partners Ltd ended 2024 with CHF 149 million in cash, cash equivalents, and short-term deposits, underscoring a sound liquidity base that secures the financial runway for its operations and ongoing clinical programs.

Advancements in Clinical Pipeline

The company updated its progress across several programs: the planned IND submission for MP0712 targeting DLL3 is on course for H1 2025 pending regulatory clearance, and early data from the MP0533 Phase 1/2a clinical trial indicates enhanced response rates. Additionally, further preclinical data from the Switch-DARPin programs is expected throughout 2025.

Strategic Partnerships & Future Milestones

Key collaborations were highlighted, notably the expanded strategic partnership with Orano Med, now encompassing up to ten radiotherapy programs. These partnerships, along with upcoming clinical data and regulatory submissions, position Molecular Partners Ltd for pivotal value inflection points in 2025 and beyond.

Summarized from source with an LLMView Source

Key figures

-22.6%1Y

-42.5%3Y

-83.6%5Y

Performance

58.2%1Y

61.2%3Y

67.2%5Y

Volatility